Division of Medical Oncology, University of Toronto and Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada.
Nat Rev Clin Oncol. 2010 Apr;7(4):187-8. doi: 10.1038/nrclinonc.2010.19.
The addition of zoledronic acid to aromatase inhibitors is associated with improved bone mineral density, but not with an effect on clinically-meaningful end points such as fractures. The oncology community should prioritize the design of trials evaluating more relevant end points, such as fragility fracture risk, for treatment-induced bone loss and critically assess the effects of such treatment on breast cancer survival.
唑来膦酸的加入与芳香酶抑制剂联合治疗可改善骨密度，但对骨折等有临床意义的终点没有影响。肿瘤学领域应优先设计评估更相关终点的试验，如治疗相关骨丢失的脆性骨折风险，并对这种治疗对乳腺癌生存的影响进行严格评估。
